Figure S4. The delayed activation model describes the later increase of CA-US HIV RNA after treatment cessation well in general. Among the 14 patients where the level of CA-US RNA increases after treatment is stopped, this model describes the pattern well in 6 patients (VOR001, VOR003, VOR004, VOR011, VOR013 and VOR019). It does not describe the amplitude of the increase in 8 patients (VOR002, VOR008, VOR009, VOR016-VOR018, VOR021 and VOR023). Plots show the same simulation results as in Fig. S3; however, the entire 84 days of study period are shown. Each panel shows the simulation trajectories using best-fit parameters of the delayed activation model (blue lines), and the levels of CA-US RNA measured in clinical trials. The period of vorinostat treatment is shaded in bisque.